The evolving landscape of early-phase oncology: Toward more precise drug development
European Journal of Cancer · 2026-06 · 242 · 116786
DOI: 10.1016/j.ejca.2026.116786 ↗Kurz gefasst
Editorial in der Zeitschrift European Journal of Cancer, 2026-06. Verfasst von Camille Mazza und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institut Godinot, Unité de Phases Précoces (UPP), Reims, France. Electronic address: camille.mazza@reims.unicancer.fr. Die Arbeit nennt 12 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Institut Godinot, Unité de Phases Précoces (UPP), Reims, France. Electronic address: camille.mazza@reims.unicancer.fr.
- Gustave Roussy, Drug Development Department (DITEP), Villejuif, France.
- Université Paris Saclay, Gustave Roussy, INSERM, Prédicteurs moléculaires et nouvelles cibles en oncologie (U981), Villejuif F-94805, France.
Zitieren
APA
Mazza, C., Dugage, M. R., Italiano, A., Massard, C., & Barlesi, F. (2026). The evolving landscape of early-phase oncology: Toward more precise drug development. European Journal of Cancer, 242, 116786. https://doi.org/10.1016/j.ejca.2026.116786
Vancouver
Mazza C, Dugage MR, Italiano A, Massard C, Barlesi F. The evolving landscape of early-phase oncology: Toward more precise drug development. European Journal of Cancer. 2026;242:116786. doi:10.1016/j.ejca.2026.116786
BibTeX
@article{Mazza2026,
author = {Mazza, Camille and Dugage, Matthieu Roulleaux and Italiano, Antoine and Massard, Christophe and Barlesi, Fabrice},
title = {The evolving landscape of early-phase oncology: Toward more precise drug development},
journal = {European Journal of Cancer},
year = {2026},
volume = {242},
pages = {116786},
doi = {10.1016/j.ejca.2026.116786}
}
EUVIMED